share_log

Vertex Pharmaceuticals | SC TO-C: Written communication relating to an issuer or third party tender offer

Vertex Pharmaceuticals | SC TO-C: Written communication relating to an issuer or third party tender offer

福泰制药 | SC TO-C：投标报价书面通信
SEC announcement ·  04/11 16:11
Moomoo AI 已提取核心信息
Vertex Pharmaceuticals Incorporated announced its definitive agreement to acquire Alpine Immune Sciences for $65 per share in cash, valuing the transaction at approximately $4.9 billion. The acquisition is set to enhance Vertex's portfolio with Alpine's lead asset, povetacicept, a Phase III-ready molecule for IgA nephropathy (IgAN), and other potential therapies. Povetacicept is also being evaluated for other serious immune renal diseases and cytopenias. The transaction, expected to close this quarter, will be funded through cash on hand. Vertex aims to leverage its clinical, regulatory, and commercial capabilities to expedite the development and commercialization of povetacicept, targeting approval in IgAN by 2027. The acquisition aligns with Vertex's strategy of focusing on transformative therapies for serious diseases and adds protein engineering and immunotherapy expertise to its capabilities. The tender offer for Alpine's outstanding shares has not yet commenced, and the related Tender Offer Materials and Solicitation/Recommendation Statement will be filed with the SEC and made available to Alpine's stockholders.
Vertex Pharmaceuticals Incorporated announced its definitive agreement to acquire Alpine Immune Sciences for $65 per share in cash, valuing the transaction at approximately $4.9 billion. The acquisition is set to enhance Vertex's portfolio with Alpine's lead asset, povetacicept, a Phase III-ready molecule for IgA nephropathy (IgAN), and other potential therapies. Povetacicept is also being evaluated for other serious immune renal diseases and cytopenias. The transaction, expected to close this quarter, will be funded through cash on hand. Vertex aims to leverage its clinical, regulatory, and commercial capabilities to expedite the development and commercialization of povetacicept, targeting approval in IgAN by 2027. The acquisition aligns with Vertex's strategy of focusing on transformative therapies for serious diseases and adds protein engineering and immunotherapy expertise to its capabilities. The tender offer for Alpine's outstanding shares has not yet commenced, and the related Tender Offer Materials and Solicitation/Recommendation Statement will be filed with the SEC and made available to Alpine's stockholders.
Vertex Pharmicals Incorporated宣布了以每股65美元现金收购Alpine Immune Sciences的最终协议，交易估值约为49亿美元。此次收购将通过Alpine的主要资产povetacicept（一种用于IgA肾病（IGaN）的III期准备分子以及其他潜在疗法来增强Vertex的产品组合。Povetacicept还正在评估其他严重的免疫性肾脏疾病和血细胞减少症。该交易预计将于本季度完成，资金将来自手头现金。Vertex的目标是利用其临床、监管和商业能力来加快povetacept的开发和商业化，目标是到2027年在iGaN获得批准。此次收购符合Vertex专注于严重疾病变革性疗法的战略，并为其能力增加了蛋白质工程和免疫疗法的专业知识。阿尔派已发行股票的要约尚未开始，相关的要约材料和招标/建议声明将提交给美国证券交易委员会，并提供给阿尔派的股东。
Vertex Pharmicals Incorporated宣布了以每股65美元现金收购Alpine Immune Sciences的最终协议，交易估值约为49亿美元。此次收购将通过Alpine的主要资产povetacicept（一种用于IgA肾病（IGaN）的III期准备分子以及其他潜在疗法来增强Vertex的产品组合。Povetacicept还正在评估其他严重的免疫性肾脏疾病和血细胞减少症。该交易预计将于本季度完成，资金将来自手头现金。Vertex的目标是利用其临床、监管和商业能力来加快povetacept的开发和商业化，目标是到2027年在iGaN获得批准。此次收购符合Vertex专注于严重疾病变革性疗法的战略，并为其能力增加了蛋白质工程和免疫疗法的专业知识。阿尔派已发行股票的要约尚未开始，相关的要约材料和招标/建议声明将提交给美国证券交易委员会，并提供给阿尔派的股东。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息